Pre-made Benralizumab benchmark antibody ( Whole mAb, anti-IL5RA therapeutic antibody, Anti-CD125/CDw125/HSIL5R3/IL5R Antibody) for drug discovery and mechanism of action (MOA) researchCat No.: GMP-Bios-ab-058
Pre-Made Benralizumab biosimilar, Whole mAb, Anti-IL5RA Antibody: Anti-CD125/CDw125/HSIL5R3/IL5R therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Benralizumab, sold under the brand name Fasenra, is a monoclonal antibody medication which is developed by MedImmune for the treatment of asthma. It is directed against the alpha-chain of the interleukin-5 receptor (CD125).
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
|Catalog No.||Package||Price(In USD)||Qty (Quantity)||Sum(In USD)|
|Products Name (INN Index)||Pre-Made Benralizumab biosimilar, Whole mAb, Anti-IL5RA Antibody: Anti-CD125/CDw125/HSIL5R3/IL5R therapeutic antibody|
|Highest_Clin_Trial (Jan '20)||Approved|
|100% SI Structure||None|
|99% SI Structure||None|
|95-98% SI Structure||None|
|Companies||AstraZeneca;Cincinnati Children's Hospital Medical Center;Kyowa Hakko;Kyowa Hakko Kirin;McMaster University;MedImmune;National Jewish Medical and Research Center;BioWa|
|Conditions Active||Chronic obstructive pulmonary disease;Nasal polyps;Atopic dermatitis;Churg-Strauss syndrome;Hypereosinophilic syndrome;Rhinosinusitis;Eosinophilic gastroenteritis|
|Conditions Discontinued||Skin disorders|
|Development Tech||POTELLIGENT Technology|